Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort

Background: Metabolic syndrome (MetS) is a highly prevalent and harmful medical disorder often comorbid with psychosis where it can contribute to cardiovascular complications. As immune dysfunction is a key shared component of both MetS and schizophrenia (SZ), this study investigated the relationship between immune alterations and MetS in patients with SZ, whilst controlling the impact of confounding clinical characteristics including psychiatric symptoms and comorbidities, history of childhood maltreatment and psychotropic treatments. Method: A total of 310 patients meeting DSM-IV criteria for SZ or schizoaffective disorders (SZA), with or without MetS, were systematically assessed and included in the FondaMental Advanced Centers of Expertise for Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients, including psychotic symptomatology, psychiatric comorbidities and history of childhood maltreatment were recorded and the serum levels of 18 cytokines were measured. A penalized regression method was performed to analyze associations between inflammation and MetS, whilst controlling for confounding factors. Results: Of the total sample, 25% of patients had MetS. Eight cytokines were above the lower limit of detection (LLOD) in more than 90% of the samples and retained in downstream analysis. Using a conservative Variable Inclusion Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6, IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α were associated with MetS. As for clinical variables, age, sex, body mass index (BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP), alcohol abuse, current tobacco smoking, and treatment with antidepressants and anxiolytics were all associated with MetS. Conclusion: We have identified five cytokines associated with MetS in SZ suggesting that patients with psychotic disorders and MetS are characterized by a specific “immuno-metabolic” profile. This may help to design tailored treatments for this subgroup of patients with both psychotic disorders and MetS, taking one more step towards precision medicine in psychiatry. © 2022 The AuthorsImmuno-Génétique, Inflammation, retro-Virus, Environnement : de l'étiopathogénie des troubles psychotiques aux modèles animauxRéseau d'Innovation sur les Voies de Signalisation en Sciences de la Vi

Polarization of charge-transfer bands and rectification in hexadecylquinolinium 7,7,8-tricyanoquinodimethanide and its tetrafluoro analog

A Langmuir-Blodgett (LB) multilayer film of the unimolecular rectifier hexadecyl-gamma-quinolinium-7,7,8-tricyanoquinodimethanide (C(16)H(33)gammaQ-3CNQ) has two distinct polarized charge-transfer bands, one at lower film pressures (28 mN m(-1)) with a peak at 530 nm, due to an intramolecular charge transfer or intervalence transfer (IVT); past the collapse point (32 to 35 mN m(-1)), this band disappears, and a new intermolecular charge-transfer band appears with peak at 570 nm. An LB multilayer film of the tetrafluoro analogue, hexadecyl-gamma-quinolinium-2,3,5,6-tetrafluoro-7,7,8-tricyanoquinodimethanide (C(16)H(33)gammaQ-3CNQF(4)) shows, for all film pressures, only one IVT band with a peak at 504 nm; when sandwiched between gold electrodes, (C(16)H(33)gammaQ-3CNQF(4) is also an LB monolayer electrical rectifier

Spectroscopy and rectification of three donor−sigma−acceptor compounds, consisting of a one-electron donor (pyrene or ferrocene), a one-electron acceptor (perylenebisimide), and a C19 swallowtail

We report spectroscopic characterization and unimolecular rectification (asymmetric electrical conduction) measurements of three donor-sigma-acceptor (D-sigma-A) compounds N-(10-nonadecyl)-N-(1-pyrenylmethyl)perylene-3,4,9,10-bis(dicarboximide) (1), N-(10-nonadecyl)-N-(4-[1-pyrenyl]butyl)perylene-3,4,9,10-bis(dicarboximide) (2), and N-(10-nonadecyl)-N-(2-ferrocenylethyl)perylene-3,4,9,10-bis(dicarboximide) (3). These molecules were arranged as one-molecule thick Langmuir-Blodgett monolayers between Au electrodes. In such an "Au | D-sigma-A | Au" sandwich, molecule 1 is a unimolecular rectifier, with rather small rectification ratios (between 2 and 3 at +/-1 V) that decrease upon cycling. Molecule 2 does not rectify. Molecule 3 rectifies, with a rectification ratio of between 14 and 28 at +/-1 V; the through-film rectification and currents persist, even with scans of +/-2 V, for up to 40 cycles of measurement. Qualitative arguments, based on a two-level rectification mechanism, are consistent with the current asymmetries observed in the monolayers of 1 and 3